Bio-Rad Laboratories (BIO) Expected to Announce Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect Bio-Rad Laboratories to post earnings of $1.73 per share and revenue of $573.01 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Stock Down 0.3 %

Shares of BIO stock traded down $0.77 during trading hours on Tuesday, reaching $239.40. 56,483 shares of the stock were exchanged, compared to its average volume of 312,833. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories has a 12-month low of $215.38 and a 12-month high of $387.99. The business's fifty day moving average is $250.16 and its two-hundred day moving average is $307.44. The firm has a market capitalization of $6.71 billion, a P/E ratio of -3.68 and a beta of 1.12.

Analyst Ratings Changes

A number of research firms have recently issued reports on BIO. Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $380.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.